Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade

Intrinsic cross-resistance to inhibition of different signaling pathways may hamper development of combinatorial treatments in melanoma, but the relative frequency of this phenotype and the strategies to overcome this hurdle remain poorly understood. Among 49 BRAF-mutant melanoma cell lines from pat...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Penna, Ilaria, Molla, Alessandra, Grazia, Giulia, Cleris, Loredana, Nicolini, Gabriella, Perrone, Federica, Picciani, Benedetta, Del Vecchio, Michele, de Braud, Filippo, Mortarini, Roberta, Anichini, Andrea
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2015
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4826182/
https://ncbi.nlm.nih.gov/pubmed/26678033
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6600
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items